WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, September 05, 2003

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR	
☐	L7	L6 and (quartnerary ammoni?)	11
☐	L6	L5 and ((polyethylene glycol) or (hydroxy stearic) or (acid glyceride?))	34
☐	L5	L3 and (deionized water)	34
☐	L4	L3 and (nipagin or nipasol)	1
☐	L3	L2 and ((propylene glycol) or glerol or glycol$)	35
☐	L2	L1 and (acetate? or citrate? or ascorbate? or phosphate?)	36
☐	L1	ibandron$ and (osteogen$ or bone or osseous or skeletal$)	253

END OF SEARCH HISTORY

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:
x
Welcome to STN International!  Enter x:
LOGINID:ssspta1153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  Feb 24   PCTGEN now available on STN
 NEWS  4  Feb 24   TEMA now available on STN
 NEWS  5  Feb 26   NTIS now allows simultaneous left and right truncation
 NEWS  6  Feb 26   PCTFULL now contains images
 NEWS  7  Mar 04   SDI PACKAGE for monthly delivery of multifile SDI results
 NEWS  8  Mar 24   PATDPAFULL now available on STN
 NEWS  9  Mar 24   Additional information for trade-named substances without
                   structures available in REGISTRY
 NEWS 10  Apr 11   Display formats in DGENE enhanced
 NEWS 11  Apr 14   MEDLINE Reload
 NEWS 12  Apr 17   Polymer searching in REGISTRY enhanced
 NEWS 13  AUG 22   Indexing from 1927 to 1936 added to records in CA/CAPLUS
 NEWS 14  Apr 21   New current-awareness alert (SDI) frequency in
                   WPIDS/WPINDEX/WPIX
 NEWS 15  Apr 28   RDISCLOSURE now available on STN
 NEWS 16  May 05   Pharmacokinetic information and systematic chemical names
                   added to PHAR
 NEWS 17  May 15   MEDLINE file segment of TOXCENTER reloaded
 NEWS 18  May 15   Supporter information for ENCOMPPAT and ENCOMPLIT updated
 NEWS 19  May 19   Simultaneous left and right truncation added to WSCA
 NEWS 20  May 19   RAPRA enhanced with new search field, simultaneous left and
                   right truncation
 NEWS 21  Jun 06   Simultaneous left and right truncation added to CBNB
 NEWS 22  Jun 06   PASCAL enhanced with additional data
 NEWS 23  Jun 20   2003 edition of the FSTA Thesaurus is now available
 NEWS 24  Jun 25   HSDB has been reloaded
 NEWS 25  Jul 16   Data from 1960-1976 added to RDISCLOSURE
 NEWS 26  Jul 21   Identification of STN records implemented
 NEWS 27  Jul 21   Polymer class term count added to REGISTRY
 NEWS 28  Jul 22   INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
                   Right Truncation available
 NEWS 29  AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                   August 1, 2003
 NEWS 30  AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS 31  AUG 15   PATDPAFULL: one FREE connect hour, per account, in
                   September 2003
 NEWS 32  AUG 15   PCTGEN: one FREE connect hour, per account, in
                   September 2003
 NEWS 33  AUG 15   RDISCLOSURE: one FREE connect hour, per account, in
                   September 2003
 NEWS 34  AUG 15   TEMA: one FREE connect hour, per account, in
                   September 2003
 NEWS 35  AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS 36  AUG 18   Simultaneous left and right truncation added to PASCAL
```

```
 NEWS 37  AUG 18  FROSTI and KOSMET enhanced with Simultaneous Left and Right
                  Truncation
 NEWS 38  AUG 18  Simultaneous left and right truncation added to ANABSTR

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:38:41 ON 05 SEP 2003

=> file caplus uspatful japio europatful medline biosis embase
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CAPLUS' ENTERED AT 15:39:10 ON 05 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:39:10 ON 05 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:39:10 ON 05 SEP 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 15:39:10 ON 05 SEP 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 15:39:10 ON 05 SEP 2003

FILE 'BIOSIS' ENTERED AT 15:39:10 ON 05 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 15:39:10 ON 05 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

=> s ibandron? and (osteogen? or bone or osseous or skeletal)
L1        1101 IBANDRON? AND (OSTEOGEN? OR BONE OR OSSEOUS OR SKELETAL)

=> s l1 and (acetate# or citr? or ascorbate# or phosphate#)
L2         295 L1 AND (ACETATE# OR CITR? OR ASCORBATE# OR PHOSPHATE#)

=> s l2 and ((polyethylene gl;ycol) or (propylene glycol) or (acid glyceride#))
UNMATCHED LEFT PARENTHESIS 'AND ((POLYETHYLE'
COMMAND STACK INTERRUPTED.  ENTER "DISPLAY HISTORY"
TO SEE WHICH COMMANDS WERE EXECUTED.
```

The number of right parentheses in a query must be equal to the number of left parentheses.

=> s l2 and ((polyethylene glycol) or (propylene glycol) or (acid glyceride#))
L3 199 L2 AND ((POLYETHYLENE GLYCOL) OR (PROPYLENE GLYCOL) OR (ACID GLYCERIDE#))

=> s l3 and (nipagin or nipasol or borate? or boric?)
L4 47 L3 AND (NIPAGIN OR NIPASOL OR BORATE? OR BORIC?)

=> s l4 and (deionized water)
L5 20 L4 AND (DEIONIZED WATER)

=> s l5 and (sorbitol or sweetener# or adjvant# or excipient#)
L6 20 L5 AND (SORBITOL OR SWEETENER# OR ADJVANT# OR EXCIPIENT#)

=> d l6 1-20 ibib abs

L6 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:591663 CAPLUS
DOCUMENT NUMBER: 137:129921
TITLE: Liquid pharmaceutical composition containing **ibandronate** for treating **bone** diseases
INVENTOR(S): Uria, Guadalupe Martinez
PATENT ASSIGNEE(S): Riderway Corporation, Panama
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1228761	A2	20020807	EP 2002-1959	20020201
EP 1228761	A3	20030115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002142997	A1	20021003	US 2002-66008	20020201
JP 2002332235	A2	20021122	JP 2002-25725	20020201
BR 2002000291	A	20030701	BR 2002-291	20020201
PRIORITY APPLN. INFO.:			US 2001-265827P P	20010201
			AR 2001-106109 A	20011228

AB A liq. pharmaceutical compn. and methods for use in the treating of **bone** diseases, comprise an aq. soln. contg. 0.05-35% by wt. of **ibandronic** acid or its salts, 0.1-5% by wt. of a pH regulating agent, 1-15% by wt. of a co-solvent, 0.005%-0.5% by wt. of a conserving agent, 1-90% by wt. of a **deionized water**, and **excipients** and pharmaceutically acceptable stabilizers, wherein the compn. has a pH of about 2-7. The compn. is formulated for sublingual administration and enteric administration. For example, a compn. for sublingual administration was prepd. by dissolving 1200 mg of monohydrate **citric** acid in **deionized water** to obtain equiv. to 22%, adding 2810 mg of aq. sodium **ibandronate** followed by 20 mg of **propylene glycol** with agitation, adjusting the pH to 2.4, and adding **deionized water** to bring the formulation to 100 g followed by filtering.

L6 ANSWER 2 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:259424 USPATFULL
TITLE: Liquid pharmaceutical composition for treating **bone** diseases
INVENTOR(S): Uria, Guadalupe Martinez, Buenos Aires, ARGENTINA

PATENT ASSIGNEE(S): RIDERWAY CORPORATION (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142997	A1	20021003
APPLICATION INFO.:	US 2002-66008	A1	20020201 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-265827P	20010201 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DARBY & DARBY P.C., 805 Third Avenue, New York, NY, 10022
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a liquid pharmaceutical composition and methods for use in the treating of **bone** diseases, the composition being an aqueous solution comprising 0.05% to 35% by weight of **ibandronaic** acid or salts thereof; 0.1% to 5% by weight of a pH regulating agent; 1% to 15% by weight of a co-solvent; 0.005% to 0.5% by weight of a conserving agent; 1% to 90% by weight of a **deionized water**; and **excipients** and pharmaceutically acceptable stabilizers, wherein the composition has a pH of about 2 to 7. The composition is formulated for sublingual administration and enteric administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:160717 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Newbury Park, CA, United States
Smith, Garry R., Limerick, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6413955	B1	20020702
APPLICATION INFO.:	US 2000-677677		20001002 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157490P	19991004 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Patel, Sudhaker B.
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory

arthritis, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:152632 USPATFULL
TITLE: .alpha.v integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6410526	B1	20020625	
APPLICATION INFO.:	US 2000-583522		20000531	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-137101P	19990602	(60)
	US 2000-179216P	20000131	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Coleman, Brenda
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and .alpha.v.beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:92700 USPATFULL
TITLE: Alpha v integrin receptor antagonists
INVENTOR(S): Arison, Byron H., Watchung, NJ, UNITED STATES
Cui, Donghui, Newton, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Lansdale, PA, UNITED STATES
Subramanian, Raju, Perkasie, PA, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002049224	A1	20020425	
	US 6426353	B2	20020730	
APPLICATION INFO.:	US 2001-952084	A1	20010914	(9)

	NUMBER	DATE

PRIORITY INFORMATION: US 2000-232344P 20000914 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1088
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting **bone** resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting **bone** resorption and for the treatment and prevention of osteoporosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:72890 USPATFULL
TITLE: Alpha V integrin receptor antagonists
INVENTOR(S): Coleman, Paul J., Wallingford, PA, UNITED STATES
Cui, Donghui, Newtown, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Landsdale, PA, UNITED STATES
Silva Elipe, Maria Victoria, Mountainside, NJ, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002040030	A1	20020404
APPLICATION INFO.:	US 2001-953606	A1	20010914 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232262P	20000914 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1296
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R.dbd.H or Me), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting **bone** resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting **bone** resorption and for the treatment and prevention of osteoporosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:67236 USPATFULL
TITLE: Alpha V integrin receptor antagonists

INVENTOR(S): Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Li, Aiwen, Audubon, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Perkins, James J., Churchville, PA, UNITED STATES
Steele, Thomas G., Schwenksville, PA, UNITED STATES
Wang, Jiabing, Chalfont, PA, UNITED STATES
Patane, Michael A., Billerica, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002037889	A1	20020328	
	US 6472403	B2	20021029	
APPLICATION INFO.:	US 2001-766148	A1	20010119	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-177168P	20000120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 2835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:57802 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Perkins, James J., Churchville, PA, United States
Ihle, Nathan, Mercer Island, WA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6358970	B1	20020319	
APPLICATION INFO.:	US 2000-599088		20000621	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-140535P	19990623 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2558

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:17296 USPATFULL

TITLE: Integrin receptor antagonists

INVENTOR(S): Askew, Ben C., Lansdale, PA, UNITED STATES
Coleman, Paul J., Wallingford, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hartman, George D., Lansdale, PA, UNITED STATES
Hunt, Cecilia A., Plymouth Meeting, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Patane, Michael A., Harleysville, PA, UNITED STATES
Smith, Garry R., Limerick, PA, UNITED STATES
Wang, Jiabing, Lansdale, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010176	A1	20020124
APPLICATION INFO.:	US 2001-916977	A1	20010728 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-454847, filed on 7 Dec 1999, PENDING Division of Ser. No. US 1998-212082, filed on 15 Dec 1998, GRANTED, Pat. No. US 6048861

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69899P	19971217 (60)
	US 1998-83209P	19980427 (60)
	US 1998-92622P	19980713 (60)
	US 1998-108063P	19981112 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907

NUMBER OF CLAIMS: 40

EXEMPLARY CLAIM: 1

LINE COUNT: 5336

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2001:233621 USPATFULL

TITLE: Alpha V integrin receptor antagonists

INVENTOR(S): Askew, Ben C., Newbury Park, CA, United States
Breslin, Michael J., Drexel Hill, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Steele, Thomas G., Schwenksville, PA, United States
Patane, Michael A., Billerica, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001053853	A1	20011220
APPLICATION INFO.:	US 2001-767471	A1	20010123 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-177792P	20000124 (60)
	US 2000-230469P	20000906 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 4132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:168133 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Patane, Michael A., Harleysville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6297249	B1	20011002
APPLICATION INFO.:	US 1999-453847		19991202 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-212082, filed on 15 Dec 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69899P	19971217 (60)
	US 1998-83209P	19980427 (60)
	US 1998-92622P	19980713 (60)
	US 1998-108063P	19981112 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Rao, Deepak R.
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin

NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 4784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:121485 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6268378	B1	20010731
APPLICATION INFO.:	US 2000-498895		20000207 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-212123, filed on 15 Dec 1998, now patented, Pat. No. US 6066648, issued on 23 May 2000

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69910P	19971217 (60)
	US 1998-83251P	19980427 (60)
	US 1998-92588P	19980713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Solola, Taofiq A.
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 4460
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:71543 USPATFULL
TITLE: Bezazepine derivatives as .alpha.v integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232308	B1	20010515
APPLICATION INFO.:	US 2000-496525		20000202 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-118428P	19990203 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1967
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to benzazepine derivatives and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:48064 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211191	B1	20010403
APPLICATION INFO.:	US 1998-212510		19981215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69909P	19971217 (60)
	US 1998-83250P	19980427 (60)
	US 1998-92630P	19980713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
ASSISTANT EXAMINER: Jayaram, Beby
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 3544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting

vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:92099 USPATFULL
TITLE: Alkanoic acid derivatives as .alpha.v integrin receptor antagonists
INVENTOR(S): Hutchinson, John H., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6090944		20000718	
APPLICATION INFO.:	US 1999-371444		19990810	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-96378P	19980813	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1,24
LINE COUNT: 3589
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:64874 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6066648		20000523	
APPLICATION INFO.:	US 1998-212123		19981215	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-69910P	19971217	(60)
	US 1998-83251P	19980427	(60)
	US 1998-92588P	19980713	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann

ASSISTANT EXAMINER: Keating, Dominic
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 4780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:44101 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hartman, George D., Lansdale, PA, United States
Hunt, Cecilia A., Plymouth Meeting, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Smith, Garry R., Limerick, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6048861		20000411	
APPLICATION INFO.:	US 1998-212082		19981215	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-69899P	19971217	(60)
	US 1998-83209P	19980427	(60)
	US 1998-92622P	19980713	(60)
	US 1998-108063P	19981112	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Rao, Deepak R.
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
LINE COUNT: 5443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor

growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:34557 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6040311		20000321	
APPLICATION INFO.:	US 1999-362528		19990728	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-94478P	19980729	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 2801
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5 and/or .alpha..nu..beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:9915 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6017926		20000125	
APPLICATION INFO.:	US 1998-212079		19981215	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-69910P	19971217	(60)
	US 1998-83251P	19980427	(60)

	US 1998-92588P	19980713 (60)
	US 1998-79197P	19980324 (60)
	US 1998-79944P	19980330 (60)
	US 1998-80397P	19980402 (60)
	US 1998-92624P	19980713 (60)
	US 1998-99948P	19980911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dentz, Bernard	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5668	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 20 EUROPATFULL COPYRIGHT 2003 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER:	1228761 EUROPATFULL EW 200232 FS OS
TITLE:	Liquid pharmaceutical composition for treating **bone** diseases. Fluessige pharmazeutische Zusammensetzung zur Behandlung von Knochenerkrankungen. Composition pharmaceutique liquide pour le traitement de maladies osseuses.
INVENTOR(S):	Uria, Guadalupe Martinez, Avenida Juan B. Justo 4840 (1416), Capital Federal, AR
PATENT ASSIGNEE(S):	Riderway Corporation, Elvira Mendez, Edificio Villarino, Piso 6, Panama, PA
PATENT ASSIGNEE NO:	4010580
AGENT:	Frohwitter, Bernhard, Dipl.-Ing., Patent- und Rechtsanwaelte, Postfach 86 03 68, 81630 Muenchen, DE
AGENT NUMBER:	150675
OTHER SOURCE:	BEPA2002066 EP 1228761 A2 0011
SOURCE:	Wila-EPZ-2002-H32-T1b
DOCUMENT TYPE:	Patent
LANGUAGE:	Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES:	R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE:	EPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1228761	A2	20020807

'OFFENLEGUNGS' DATE:		20020807
APPLICATION INFO.:	EP 2002-1959	20020201
PRIORITY APPLN. INFO.:	US 2001-265827	20010201
	AR 2001-106109	20011228

East

	Inventor	S	C	P	2	3	4	5	Image Doc. Displayed	PT
1	Uria, Guadalupe Martinez	☒	☐	☐	☐	☐	☐	☐	US 20020142997	☐

Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: L6 and (quartnerary ammoni?)

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Friday, September 05, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L7	L6 and (quartnerary ammoni?)	11	L7
L6	L5 and ((polyethylene glycol) or (hydroxy stearic) or (acid glyceride?))	34	L6
L5	L3 and (deionized water)	34	L5
L4	L3 and (nipagin or nipasol)	1	L4
L3	L2 and ((propylene glycol) or glerol or glycol$)	35	L3
L2	L1 and (acetate? or citrate? or ascorbate? or phosphate?)	36	L2
L1	ibandron$ and (osteogen$ or bone or osseous or skeletal$)	253	L1

END OF SEARCH HISTORY

	Type	L #	Hits	Search Text	DBs	Time Stamp
1	BRS	L1	253	ibandron$ and (osdtegen$ or bone or osseous or skeletal$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/09/05 19:38
2	BRS	L2	253	ibandron$ and (osteogen$ or bone or osseous or skeletal$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/09/05 19:39
3	BRS	L3	148	l2 and (acetate? or citrate or ascorbate? or phosphate?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/09/05 19:39
4	BRS	L4	148	l3 and ((propylene glycol) or glycerol or glycol$ or (polyethylene glycol) or (acid glyceride?))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/09/05 19:41
5	BRS	L5	1	l4 and (nipagin or nipasol or borate? or boric?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/09/05 19:42

	Comments	Error Definition	Errors
1			0
2			0
3			0
4			0
5			0

	Title	Current OR	Current XRef	Retrieval Classif
1	Liquid pharmaceutical composition for treating bone diseases	514/102		

	U	1	Document ID	Issue Date	Pages
1	☐	☐	US 20020142997 A1	20021003	7